OBJECTIVE： To systematically evaluate the effects of atorvastatin on pulmonary function， pulmonary arterial pressure and related indexes in patients with stable chronic obstructive pulmonary disease （COPD）， and to provide evidence-based reference. METHODS： Retrieved from Cochrane Library，PubMed，EMBase，CJFD and VIP， randomized controlled trials（RCTs）about atorvastatin combined with conventional therapy （trial group） vs. conventional therapy alone （control group） in the treatment of stable COPD were collected.  Meta-analysis was performed by using Rev Man 5.3 statistical software after data extraction and quality evaluation by Cochrane Handbook Manual 5.1.0. RESULTS： Totally 7 RCTs were included， involving 371 patients. Results of Meta-analysis showed， FEV1 [MD＝0.07， 95％CI（0.04，0.09），P＜0.001]， FEV1％pred [MD＝6.18， 95％CI（2.23，10.12）， P＝0.002] and 6MWD [MD＝55.31，95％CI（36.44，74.18），P＜0.001] of trial group were significantly higher/longer than those of control group； pulmonary artery systolic pressure [MD＝－6.78， 95％CI（－11.62，－1.94），P＝0.006]， mean pulmonary artery pressure [MD＝－6.61，95％CI（－7.26，－5.96），P＜0.001]， St. George respiratory questionnaire [MD＝－13.21， 95％CI（－23.90，－2.52），P＝0.02] were significantly lower than control group， with statistical significance. There was no statistical difference in FEV1/FVC[MD＝3.73，95％CI（－2.08，9.55），P＝0.21] or hs-CRP [MD＝0.29， 95％CI（－1.37，1.95），P＝0.73] between 2 groups. CONCLUSIONS： Atorvastatin can significantly improve pulmonary function and pulmonary arterial pressure in patients with stable COPD， and can improve the quality of life.